Phase 3 Study Comparing Xaluritamig with Cabazitaxel or Other Hormone Therapy in Patients with Advanced Prostate Cancer

Inclusion Criteria

• Must provide informed consent before starting any study-related activities.
• Must be 18 years or older.
• Must have a confirmed diagnosis of prostate cancer.
• Must have advanced prostate cancer with at least one tumor that can be seen on a scan.
• Must show signs of cancer progression, such as rising PSA levels or new tumors.
• Must have had surgery to remove the testicles or be on hormone therapy to lower testosterone levels.
• Must have previously been treated with at least one hormone therapy and one chemotherapy drug.
• Must have good overall health with an ECOG performance status of 0 or 1.
• Must have adequate organ function.

Exclusion Criteria

• Cannot have received certain prostate-targeted therapies before.
• Cannot have had any cancer treatments or experimental drugs within 4 weeks before starting the study, except for hormone therapy.
• Cannot have had certain prostate-specific treatments within 2 months before starting the study.
• Cannot have started certain bone-strengthening treatments within 4 weeks before starting the study.
• Cannot have had radiation therapy within 4 weeks before starting the study.
• Cannot have active brain metastases.
• Cannot have unresolved side effects from previous cancer treatments, except for hair loss or stable, well-controlled side effects.